NICO Corporation

Dedicated to revolutionizing minimally invasive neurosurgery

Home » Our Clinical & Economic Impact

Evidence is Mounting

  • 40,000+ Patient Lives Impacted

  • 35+ Presentations at National and International Neurosurgical Conferences

  • 150+ Peer-reviewed Publications and Abstracts

These independent publications show:

  • Repeated Safety;
  • Efficiency; and
  • Reduced Surgical Morbidity

associated with a wide range of abnormalities when using NICO technologies as a standardized method for contributing to improved clinical outcomes.

NICO supports healthcare’s commitment to achieving the Triple Aim
Evidence also suggests MIPS supported by BrainPath provides economic value for the hospital when analyzing the entire episode of care. This, combined with a reduction in the ICU length of stay, improves the patient experience of care and supports healthcare’s commitment to achieving the Triple Aim.

 

 

ICH Evacuation Clinical Impact

Clinical Advantages

Using a standardized approach (trans-sulcal, parafascicular) to access bleeds and standardized technology (BrainPath for access and Myriad NOVUS to mechanically evacuate the clot) provides three clinical advantages:

  1. Intervention in an acute time period without clot stability1
  2. Effective hemostasis management using a bi-manual technique
  3. Consistent evacuation >90% of clot1,2,3,4

Selected Clinical Outcomes

  • 98.2% median clot evacuation1
  • mRS <3 in 63% of patients2
  • <15mL EOT volumes in 94 of 98 patients studied1,2,3,4
  • Statistically significant post-op GCS improvement1,3
  • Mortality Improvement (vs pre-op ICH score)1,3
  • Decrease in ICU length of stay from 12 to 45

clinical evidence-for-ICH-evaluation-NICO

Selected Economic Outcomes

  • Increased surgical options for patients vs medical management.
  • Reduction in repetitive non-contrast CT scans.3
  • Throughput
    • 55% decrease in mechanical ventilation days.3
    • 18% decrease in neuro-ICU LOS days, freeing-up neuro-ICU beds.3
    • 47% decrease in cost per patient.3

 

 

Tumor & Brain Biopsy Clinical Impact

In a 2020 Meta-Analysis published in World Neurosurgery that included 29 publications meeting rigorous inclusion criteria, more than 280 patients were included in a review of current studies on use of MIPS with BrainPath. The outcomes not only confirmed the success of non-disruptive, trans-sulcal access and the ability to achieve microsurgical techniques and hemostasis management, but also the following:

Selected Clinical Outcomes

  • Lower surgical morbidity / post-operative complications (8.3%) as compared to traditional craniotomy6
  • 80.6% of cases achieved gross total resection6
  • 100% gross total resection for colloid cyst6
  • 100% success in achieving pathologic diagnosis for all biopsy cases6

Selected Economic Outcomes

  • Several cohorts have reported shorter length of hospital stay with MIPS using BrainPath as compared to traditional craniotomy, with benefits of:
    • Minimal wound disruption6
    • Decreased risk of post-operative wound infection6
    • Lower post-operative complications6
Clinical Outcomes Tumor
economic outcomes of tumor and brain biopsy NICO

 

 

Economic Impact

Clinical paper shows substantial economic benefit to hospital.

  • Greater than 50% average reduction in ICU length of stay5
  • Average economic benefit to the hospital of $12,000 per patient for 28 patients5
  • Net estimated benefit to the bottom line of $329,6595
Economic Benefit of BrainPath Surgery

Presentations by Sid Norton

Click HERE to listen to the lead author discuss their analysis of MIPS with BrainPath in neurosurgery.

Watch video abstract presented by Sid Norton.

Sid Norton, Finance AVP for Pediatrics at Intermountain Healthcare, CFO Primary Children's HospitalSidney P Norton
Finance AVP for Pediatrics,
CFO Primary Children’s Hospital,
Intermountain Healthcare

 

Citations

  1. Bauer, et al.”Initial Single-center technical experience with the BrainPath system for acute Intracerebral hemorrhage evacuation” Operative Neurosurgery 2016
  2. Labib, et al, “The safety and feasibility of image-guided BrainPath mediated transsulcul hematoma evacuation: a Multicenter trial” Neurosurgery 4, April 2017: 515-524
  3. Sujijantarat, et al. “Trans-sulcal endoport assisted evacuation of supratentorial Intracerebral hemorrhage “Operative Neurosurgery 0:1-8,2017
  4. Rutkowski, M., Song, I., Mack, W. and Zada, G., 2020. Outcomes After Minimally Invasive Parafascicular Surgery For Intracerebral Hemorrhage: A Single-Center Experience
  5. Shah,et al. Technology that achieves the Triple Aim. ClinicoEconomics and Outcomes Research. 2017;9 519-523
  6. Mansour S. et al The use of BrainPath Tubular Retractors in the Management of Deep Brain Lesions: A Review of Current Studies. World Neurosurg. (2020) 134:155-163